DIM
RNAM

DLK Investment Management’s Avidity Biosciences RNAM Stock Holding History

DLK Investment Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,700
Closed -$411K – 100
2025
Q4 		$411K Hold
5,700
– – 0.15% 56
2025
Q3 		$248K Sell
5,700
-2,000
-26% -$80.9K 0.09% 70
2025
Q2 		$219K Buy
7,700
+100
+1% +$2.98K 0.08% 71
2025
Q1 		$224K Hold
7,600
– – 0.09% 63
2024
Q4 		$221K Hold
7,600
– – 0.09% 69
2024
Q3 		$349K Hold
7,600
– – 0.13% 66
2024
Q2 		$310K Sell
7,600
-3,500
-32% -$100K 0.13% 66
2024
Q1 		$283K Hold
11,100
– – 0.12% 67
2023
Q4 		$100K Buy
+11,100
New +$74.2K 0.05% 78

Other funds holding RNAM

CC
Corsicana & Co Corsicana, Texas $206M AUM 26.42% 1-Year Est. Return

DLK Investment Management's RNAM Position: Q1 2026 in Review

DLK Investment Management sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 5,700 shares — an estimated $411K sold.

DLK Investment Management first reported a position in RNAM in Q4 2023 and held it in 9 quarters. The position peaked at $411K in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • DLK Investment Management reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • DLK Investment Management sold 5,700 Avidity Biosciences shares in Q1 2026, an estimated $411K.
  • DLK Investment Management first reported a position in Avidity Biosciences in Q4 2023 and held it in 9 quarters.
  • DLK Investment Management's Avidity Biosciences position peaked at $411K in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on DLK Investment Management's 13F filing for Q1 2026, filed 15 Apr 2026.